Clinical Trial Detail

NCT ID NCT01515527
Title Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

acute myeloid leukemia

Therapies

Cytarabine

Cladribine

Decitabine

Age Groups: adult senior

No variant requirements are available.